About Livera
Advancing AI-driven RNA therapeutics for chronic hepatitis B.
Livera is an early-stage biotechnology company focused on developing next-generation RNA therapeutics for chronic hepatitis B. By integrating AI-powered target screening, oligonucleotide design, and translational drug development, we aim to create innovative therapies that move chronic hepatitis B treatment beyond long-term viral suppression toward functional cure.
Our Mission
Our mission is to develop transformative therapies for patients living with chronic hepatitis B by addressing both viral antigen burden and immune dysfunction.
Current antiviral therapies can effectively suppress HBV replication, but many patients still require long-term treatment and rarely achieve functional cure. Livera Thera is building a dual-function siRNA platform designed to reduce viral antigen expression while exploring immune-restorative strategies.
Why Chronic Hepatitis B
Unmet Medical Need
Chronic hepatitis B remains a major global health challenge, with millions of patients requiring lifelong treatment.
Functional Cure Gap
Existing therapies suppress viral replication, but functional cure remains difficult to achieve.
Opportunity for Innovation
RNA therapeutics, AI-driven design, and immune-modulating strategies create new possibilities for next-generation HBV treatment.
Our Platform
Livera is developing an AI-assisted platform for identifying conserved HBV target regions, designing optimized siRNA candidates, evaluating off-target risks, and prioritizing molecules for experimental validation.
Our initial focus is a dual-function siRNA therapeutic strategy for chronic hepatitis B, designed to reduce HBsAg expression and support immune reactivation.
01
AI Target Screening
Identify conserved and therapeutically relevant HBV regions across genotypes.
02
siRNA Candidate Design
Generate and optimize RNA molecules with improved potency, specificity, and developability.
03
Dual-Function Strategy
Combine viral antigen reduction with immune-restorative therapeutic logic.
Our Vision
To expand our dual-mechanism therapeutic strategy—reducing disease-related antigen burden and activating immune responses—across viral infectious diseases, neurological diseases, cardiometabolic diseases, and oncology, building a next-generation nucleic acid therapeutics platform to benefit more patients.